Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls

Zheng, Yawei; Liu, Eugene H. C.; Higgins, Julian P T; Keavney, Bernard; Lowe, G. D. O.; Collins, Rory; Danesh, John

doi:10.1016/s0140-6736(06)68263-9

Cited by 378 publications

(364 citation statements)

References 36 publications

Supporting

Mentioning

315

Contrasting

Unclassified

Order By: Relevance

“…Individually, none of the other nine gene polymorphisms investigated exhibit any association with a risk of IS or CHD when compared to the non-CVD control group, and this is in accordance with the majority of similar recent studies [23]. It is important to note that the genotype frequencies of all nine polymorphisms observed in the control group are similar to the frequencies reported in the general Greek population [24][25][26].…”

Section: Discussionsupporting

confidence: 90%

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Konialis¹,

Spengos

Iliopoulos³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Konialis¹,

Spengos

Iliopoulos³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

“…Differences in genetic polymorphisms between ethnicities might partially account for the underlying mechanism. 62 For example, factor V Leiden (G1691A) and prothrombin (G20210A) gene mutations are more common in white than in Asian individuals. 62 Differences in levels of haemostatic factors (such as fibrinogen, d-dimer, and factor VIII) and plasma endothelial activation markers (such as von Willebrand factor, intercellular adhesion molecule 1, and E-selectin) might be additional factors contributing to the ethnic disparity.…”

Section: Consensus Statementsmentioning

confidence: 99%

World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

et al. 2014

View full text Add to dashboard Cite

| Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large, phase III, randomized, controlled trials of the P2Y 12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different 'therapeutic window' of on-treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the 'East Asian paradox' has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence-based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

show abstract

“…The association between PAI-1 levels and the risk for MI is equivocal [6]. The interpretation of epidemiological information concerning PAI-1 involvement in cardiovascular outcomes is complicated by the presence of potentially confounding variables.…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that the 4G allele results in higher activity than the 5G allele because the latter contains an additional binding site for a transcriptional repressor [12]. Previous studies on the 4G/5G polymorphism support its role as a risk factor for coronary artery disease (CAD) and MI [6,13,14]. It has been proposed, however, that the association between the 4G/5G gene polymorphism and the risk for MI is considerably affected by the underlying metabolic syndrome (MetS) [15].…”

Section: Introductionmentioning

confidence: 99%

The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis

Nikolopoulos¹,

Bagos²,

Tsangaris³

et al. 2014

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: The circulating levels of plasminogen activator inhibitor type 1 (PAI-1) are increased in individuals carrying the 4G allele at position -675 of the PAI-1 gene. In turn, overexpression of PAI-1 has been found to affect both atheroma and thrombosis. However, the association between PAI-1 levels and the incidence of myocardial infarction (MI) is complicated by the potentially confounding effects of well-known cardiovascular risk factors. The current study tried to investigate in parallel the association of PAI-1 activity with the PAI-1 4G/5G polymorphism, with MI, and some components of metabolic syndrome (MetS). Methods: Using meta-analytical Mendelian randomization approaches, genotype-disease and genotype-phenotype associations were modeled simultaneously. Results: According to an additive model of inheritance and the Mendelian randomization approach, the MI-related odd ratio for individuals carrying the 4G allele was 1.088 with 95% confidence interval (CI) 1.007, 1.175. Moreover, the 4G carriers had, on average, higher PAI-1 activity than 5G carriers by 1.136 units (95% CI 0.738, 1.533). The metaregression analyses showed that the levels of triglycerides (p = 0.005), cholesterol (p = 0.037) and PAI-1 (p = 0.021) in controls were associated with the MI risk conferred by the 4G carriers. Conclusions: The Mendelian randomization meta-analysis confirmed previous knowledge that the PAI-1 4G allele slightly increases the risk for MI. In addition, it supports the notion that PAI-1 activity and established cardiovascular determinants, such as cholesterol and triglyceride levels, could lie in the etiological pathway from PAI-1 4G allele to the occurrence of MI. Further research is warranted to elucidate these interactions.

show abstract

Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls

Cited by 378 publications

References 36 publications

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis

Contact Info

Product

Resources

About